{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:19:13Z","timestamp":1787840353567,"version":"build-2784847793"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Prospective analysis of oligo-brain metastasis in Indian patients treated with SRS-only treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Between January 2017 and May 2022, 235 patients were screened and 138 histologically proven and radiologically confirmed. One to five brain metastasis patients aged more than 18 years with good Karnofsky performance status (KPS &gt;70) accrued in ethical and scientific committee-approved prospective observational study protocol for treatment with only radiosurgery (SRS) with robotic radiosurgery (CyberKnife, CK) [AIMS IRB: 2020-071; CTRI No: REF\/2022\/01\/050237]. Immobilization was performed with a thermoplastic mask, contrast CT simulation was performed with 0.625 mm slices, fused with T1 contrast\/T2 FLAIR MRI images for contouring. Planning target volume (PTV) margin of 2\u20133 mm and a dose of 20\u201330 Gy in 1\u20135 fractions. Response to treatment, new brain lesions free survival, overall survival, and toxicity profile after CK were evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results: In total,<\/jats:title>\n                    <jats:p>138 patients with 251 lesions were accrued (median age 59 years (interquartile range [IQR] 49\u201367 years; female 51%; headache in 34%, motor deficit in 7%, KPS &gt;90 in 56%; lung primary in 44%, breast in 30%; oligo-recurrence in 45%; synchronous oligo-metastases in 33%; adenocarcinoma primary in 83%). One hundred seven patients (77%) received upfront Stereotactic radiotherapy (SRS), 15 (11%) received postoperative SRS, 12 (9%) received whole brain radiotherapy (WBRT) before SRS, and 3 (2%) received WBRT plus SRS boost. The majority had solitary (56%) brain metastasis, 28% had two to three lesions, and 16% had four to five brain lesions. Frontal (39%) was the most common site. Median PTV was 15.5 mL (IQR \u2013 8.1\u201328.5 mL). Seventy-one (52%) patients were treated with single fractions, 14% with three, and 33% with five fractions. Fraction schedules were 20\u20132 4 Gy\/1fr; 27 Gy\/3fr, and 25 Gy\/5 fractions (mean BED 74.6 Gy [SD \u00b1 48.1; mean MU 16608], mean treatment time was 49 min (range 17\u2013118 min]. Twelve Gy normal brain volume was 40.8 mL (3.2%) (range 19.3\u201373.7 mL). At a mean follow-up of 15 months (SD 11.9 months; max 56 months), the mean actuarial OS after SRS-only treatment was 23.7 months (95% confidence interval [CI] 20\u201328). Further 124 (90%) patients had &gt;3 months, 108 (78%) had &gt;6 months, 65 (47%) had &gt;12 months, and 26 (19%) had &gt;24 months follow-up. Intracranial disease and extracranial disease were controlled in 72 (52.2%) and 60 (43.5%), respectively. \u201cIn-field\u201d recurrence, \u201cout-of-field,\u201d and \u201cboth in and out-of-field\u201d recurrences were in 11%, 42%, and 46%, respectively. At the last follow-up, 55 patients (40%) were alive, 75 (54%) died due to disease progression, and the status of 8 (6%) patients was not known. Among 75 patients who died, 46 (61%) had extracranial disease progression, 12 (16%) had only intracranial progression, and 8 (11%) had unrelated causes. Also, 12\/117 (9%) had radiological confirmation of radiation necrosis. Prognostication based on western patients (primary tumor type, number of lesions extracranial disease) showed similar outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>SRS alone in brain metastasis is feasible in the Indian subcontinent with similar survival outcomes, recurrence patterns, and toxicity as published in the western literature. Patient selection, dose schedule, and planning need to be standardized to have similar outcomes. WBRT can be safely omitted in Indian patients with oligo-brain metastasis. Western prognostication nomogram is applicable in the Indian patient population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/0028-3886.370470","type":"journal-article","created":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T04:06:41Z","timestamp":1692850001000},"page":"62-71","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Prospective Evaluation of Response to Treatment, Survival Functions, Recurrence Pattern and Toxicity Profile in Indian Patients with Oligo-Brain Metastasis Treated with Only SRS"],"prefix":"10.4103","volume":"71","author":[{"given":"Debnarayan","family":"Dutta","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Amrita Institute of Medical Science, Kochi, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sruti K.","family":"Reddy","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Amrita Institute of Medical Science, Kochi, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram K.","family":"Kamath","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Amrita Institute of Medical Science, Kochi, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yarlagadda","family":"Sreenija","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Amrita Institute of Medical Science, Kochi, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haridas","family":"Nair","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Amrita Institute of Medical Science, Kochi, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Sashidharan","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Amrita Institute of Medical Science, Kochi, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anoop Remesan","family":"Nair R","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Amrita Institute of Medical Science, Kochi, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KU","family":"Pushpuja","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Amrita Institute of Medical Science, Kochi, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Kannan","sequence":"additional","affiliation":[{"name":"Department of Radiology, Amrita Institute of Medical Science, Kochi, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annex","family":"Edappattu","sequence":"additional","affiliation":[{"name":"Department of Medical Physics, Amrita Institute of Medical Science, Kochi, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil K.","family":"Haridas","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Amrita Institute of Medical Science, Kochi, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wesley M.","family":"Jose","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Amrita Institute of Medical Science, Kochi, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavithran","family":"Keechilat","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Amrita Institute of Medical Science, Kochi, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,2,24]]},"reference":[{"key":"R1-20250613","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.15903.1","article-title":"Recent advances in managing brain metastasis","volume":"7","author":"Kotecha","year":"2018","journal-title":"F1000Res"},{"key":"R2-20250613","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1016\/S0140-6736(16)30825-X","article-title":"Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): Results from a phase 3, non-inferiority, randomised trial","volume":"388","author":"Mulvenna","year":"2016","journal-title":"Lancet"},{"key":"R3-20250613","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S1470-2045(17)30441-2","article-title":"Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C\/CEC\u00b73): A multicentre, randomised, controlled, phase 3 trial","volume":"18","author":"Brown","year":"2017","journal-title":"Lancet Oncol"},{"key":"R4-20250613","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1001\/jama.295.21.2483","article-title":"Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: A randomized controlled trial","volume":"295","author":"Aoyama","year":"2006","journal-title":"JAMA"},{"key":"R5-20250613","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/S1470-2045(17)30414-X","article-title":"Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: A single-centre, randomised, controlled, phase 3 trial","volume":"18","author":"Mahajan","year":"2017","journal-title":"Lancet Oncol"},{"key":"R6-20250613","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1158\/1078-0432.CCR-06-2478","article-title":"Brain metastases: The HER2 paradigm","volume":"13","author":"Lin","year":"2007","journal-title":"Clin Cancer Res"},{"key":"R7-20250613","doi-asserted-by":"crossref","first-page":"3475","DOI":"10.1200\/JCO.2015.60.9503","article-title":"Treatment of brain metastases","volume":"33","author":"Lin","year":"2015","journal-title":"J Clin Oncol"},{"key":"R8-20250613","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S0360-3016(96)00619-0","article-title":"Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials","volume":"37","author":"Gaspar","year":"1997","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R9-20250613","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/0360-3016(94)90558-4","article-title":"The choice of treatment of single brain metastasis should be based on extracranial tumor activity and age","volume":"29","author":"Noordijk","year":"1994","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R10-20250613","doi-asserted-by":"crossref","first-page":"755","DOI":"10.4103\/0028-3886.263255","article-title":"Brain metastasis: Momentum towards understanding the molecular milieu","volume":"67","author":"Chilukuri","year":"2019","journal-title":"Neurol India"},{"key":"R11-20250613","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1093\/neuonc\/now127","article-title":"Updates in the management of brain metastases","volume":"18","author":"Arvold","year":"2016","journal-title":"Neuro Oncol"},{"key":"R12-20250613","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/1748-717X-9-215","article-title":"A new prognostic instrument to predict the probability of developing new cerebral metastases after radiosurgery alone","volume":"9","author":"Huttenlocher","year":"2014","journal-title":"Radiat Oncol"},{"key":"R13-20250613","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1001\/jama.2016.9839","article-title":"Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: A randomized clinical trial","volume":"316","author":"Brown","year":"2016","journal-title":"JAMA"},{"key":"R14-20250613","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/S1470-2045(09)70263-3","article-title":"Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: A randomised controlled trial","volume":"10","author":"Chang","year":"2009","journal-title":"Lancet Oncol"},{"key":"R15-20250613","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/1748-717X-6-48","article-title":"Stereotactic radiosurgery for brain metastases: Analysis of outcome and risk of brain radionecrosis","volume":"6","author":"Minniti","year":"2011","journal-title":"Radiat Oncol"},{"key":"R16-20250613","first-page":"100","article-title":"Guidelines for multiple brain metastases radiosurgery","volume":"34","author":"Niranjan","year":"2019","journal-title":"Prog NeurolSurg"},{"key":"R17-20250613","first-page":"31","article-title":"Role of stereotactic radiosurgery for multiple (>4) brain metastases","volume":"1","author":"Suh","year":"2011","journal-title":"J Radiosurg SBRT"},{"key":"R18-20250613","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0360-3016(99)00507-6","article-title":"Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: Final report of RTOG protocol 90-05","volume":"47","author":"Shaw","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R19-20250613","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.radonc.2006.08.024","article-title":"Phase II trial of hypofractionated stereotactic radiotherapy for brain metastases: Results and toxicity","volume":"81","author":"Ernst-Stecken","year":"2006","journal-title":"Radiother Oncol"}],"container-title":["Neurology India"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/0028-3886.370470","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:21:13Z","timestamp":1787836873000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/0028-3886.370470"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/0028-3886.370470","relation":{},"ISSN":["0028-3886","1998-4022"],"issn-type":[{"value":"0028-3886","type":"print"},{"value":"1998-4022","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"2022-07-12","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-17","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}